| Recruiting | A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD NCT07275840 | Innovent Biologics Technology Limited (Shanghai R&D Center) | Phase 2 |
| Recruiting | A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD NCT06847542 | Hoffmann-La Roche | Phase 3 |
| Recruiting | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation o NCT07007065 | AbbVie | Phase 3 |
| Recruiting | Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients NCT07053358 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Recruiting | Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients NCT06929507 | University Hospital, Alexandroupolis | N/A |
| Recruiting | A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) NCT06680817 | Hoffmann-La Roche | — |
| Completed | A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participan NCT06723288 | Hoffmann-La Roche | — |
| Active Not Recruiting | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascu NCT06495918 | Ocular Therapeutix, Inc. | Phase 3 |
| Recruiting | A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration NCT06660667 | Sanofi | Phase 1 / Phase 2 |
| Completed | A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of NCT06591598 | Bayer | Phase 4 |
| Active Not Recruiting | A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Ag NCT06491914 | Regeneron Pharmaceuticals | Phase 3 |
| Recruiting | A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) NCT05562947 | Hoffmann-La Roche | Phase 3 |
| Recruiting | Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular NCT06439576 | Hoffmann-La Roche | — |
| Recruiting | Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degenerati NCT05986864 | Skyline Therapeutics (US) Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in S NCT06223958 | Ocular Therapeutix, Inc. | Phase 3 |
| Active Not Recruiting | Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) NCT06196840 | Innostellar Biotherapeutics Co.,Ltd | Phase 2 |
| Completed | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Ma NCT06190093 | Outlook Therapeutics, Inc. | Phase 3 |
| Withdrawn | A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizu NCT05126966 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) NCT05859776 | AsclepiX Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD NCT06141460 | Shanghai Refreshgene Technology Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranib NCT06231121 | Rigshospitalet, Denmark | — |
| Completed | A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO NCT06176963 | Samsung Bioepis Co., Ltd. | Phase 2 |
| Recruiting | Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD NCT05904028 | Jaeb Center for Health Research | Phase 3 |
| Completed | A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and t NCT06495203 | Bayer | — |
| Completed | Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments NCT06124677 | Rigshospitalet, Denmark | — |
| Unknown | A Study of EXG102-031 in Participants With wAMD NCT06183814 | Guangzhou Jiayin Biotech Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD NCT05972473 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 |
| Recruiting | Gene Therapy(FT-003) for Wet AMD NCT06492863 | Frontera Therapeutics | Phase 1 / Phase 2 |
| Completed | Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degenerati NCT05953012 | PharmAbcine | Phase 1 |
| Completed | Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration NCT05941715 | Medical University of Graz | Phase 4 |
| Completed | Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Deg NCT05891548 | Clearside Biomedical, Inc. | Phase 2 |
| Recruiting | A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macula NCT06213038 | Youxin Chen | Phase 1 |
| Not Yet Recruiting | Gene Therapy for Wet AMD NCT05611424 | Frontera Therapeutics | Phase 1 |
| Active Not Recruiting | Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-rela NCT05698329 | AiViva BioPharma, Inc. | Phase 1 |
| Active Not Recruiting | LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD) NCT06198413 | Innostellar Biotherapeutics Co.,Ltd | Phase 1 |
| Completed | A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration NCT05639530 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Active Not Recruiting | A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration NCT05456828 | AskGene Pharma, Inc. | Phase 1 |
| Completed | Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration NCT05643118 | Olix Pharmaceuticals, Inc. | Phase 1 |
| Completed | Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular Degeneration NCT05604989 | Seoul National University Bundang Hospital | Phase 3 |
| Completed | A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascul NCT05637255 | Sylentis, S.A. | Phase 2 |
| Active Not Recruiting | A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products NCT05476926 | Hoffmann-La Roche | — |
| Completed | A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate th NCT05569148 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age NCT06699914 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME NCT05387837 | Ashvattha Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degener NCT05536973 | Adverum Biotechnologies, Inc. | Phase 2 |
| Completed | A Study of Longer Interval of IVT IBI302 in Subjects With nAMD NCT05403749 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Active Not Recruiting | TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration NCT05461339 | BioDlink Biopharm Co., Ltd. | Phase 3 |
| Completed | Safety and Efficacy of AM712 in Patients with NAMD NCT05345769 | AffaMed Therapeutics Limited | Phase 1 |
| Terminated | Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting NCT05266495 | Novartis Pharmaceuticals | — |
| Completed | Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degenerat NCT05275205 | Unity Biotechnology, Inc. | Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administrati NCT05105607 | Ashvattha Therapeutics, Inc. | Phase 1 |
| Completed | Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescript NCT06021366 | Novartis Pharmaceuticals | — |
| Unknown | Maximum Treatment Interval With Aflibercept T&E NCT05342857 | Shin Kong Wu Ho-Su Memorial Hospital | — |
| Recruiting | A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration NCT04853251 | Genentech, Inc. | Phase 4 |
| Unknown | Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD) NCT05831007 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Completed | Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Br NCT06178770 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases NCT05099094 | Shanghai BDgene Co., Ltd. | EARLY_Phase 1 |
| Terminated | Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice NCT05112835 | Novartis Pharmaceuticals | — |
| Suspended | Evaluation of IBI302 Injection in nAMD or DME NCT05961007 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual I NCT05112861 | Outlook Therapeutics, Inc. | Phase 3 |
| Completed | The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT NCT05202587 | Notal Vision Inc. | — |
| Completed | Development of an Optimal Algorithm for the Management of Patients With Retinal Pigment Epithelium Detachment NCT05208931 | The S.N. Fyodorov Eye Microsurgery State Institution | — |
| Completed | Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD) NCT04304755 | Oslo University Hospital | Phase 2 |
| Completed | Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Tr NCT04774926 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study NCT05131646 | Clearside Biomedical, Inc. | — |
| Completed | Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study NCT05281042 | Notal Vision Inc. | — |
| Recruiting | Regulatory Post-Marketing Surveillance Study for Brolucizumab NCT04985487 | Novartis Pharmaceuticals | — |
| Completed | Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration NCT04989699 | Ocular Therapeutix, Inc. | Phase 1 |
| Unknown | Home OCT Fluid Visualization Agreement Study NCT04907409 | Notal Vision Inc. | — |
| Completed | Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With N NCT04864834 | Sandoz | Phase 3 |
| Completed | A Study of IBI302 in Patients With nAMD NCT04820452 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Completed | A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Re NCT04777201 | Hoffmann-La Roche | Phase 3 |
| Terminated | OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) NCT04757636 | Opthea Limited | Phase 3 |
| Terminated | OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) NCT04757610 | Opthea Limited | Phase 3 |
| Completed | A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment NCT04662944 | Novartis Pharmaceuticals | — |
| Completed | RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) NCT04832724 | AbbVie | Phase 2 |
| Completed | A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degenerat NCT04239027 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degenerat NCT04684394 | Gemini Therapeutics, Inc. | Phase 2 |
| Recruiting | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One NCT04704921 | AbbVie | Phase 2 / Phase 3 |
| Terminated | Russian Registry of Patients With nAMD NCT04935411 | Novartis Pharmaceuticals | — |
| Completed | An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients NCT04597632 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular NCT04626128 | Clearside Biomedical, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT] NCT04645212 | Adverum Biotechnologies, Inc. | — |
| Completed | Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macula NCT04264819 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular NCT04641234 | Bayer | — |
| Completed | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients NCT04635800 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injectio NCT04563299 | Retina Vitreous Associates of Florida | Phase 4 |
| Completed | A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD NCT04632056 | Novartis Pharmaceuticals | — |
| Completed | Single In-Clinic Encounter With the Notal Vision Home OCT NCT04642183 | Notal Vision Inc. | — |
| Completed | Time Efficiency Comparison of Two IntraVitreal Injection Techniques NCT04455399 | Peregrine Eye and Laser Institute | N/A |
| Completed | Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Ma NCT04537884 | Unity Biotechnology, Inc. | Phase 1 |
| Completed | A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders NCT04516278 | Outlook Therapeutics, Inc. | Phase 3 |
| Completed | Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucenti NCT04690556 | Lupin Ltd. | Phase 3 |
| Active Not Recruiting | The Sahlgrenska Anti-VEGF Study NCT04101877 | Vastra Gotaland Region | Phase 2 |
| Completed | Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration NCT04422899 | AiViva BioPharma, Inc. | Phase 1 |
| Completed | A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) NCT04480463 | Sam Chun Dang Pharm. Co. Ltd. | Phase 3 |
| Completed | Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder T NCT04423718 | Bayer | Phase 3 |
| Completed | Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular NCT04522167 | Bioeq GmbH | Phase 3 |
| Terminated | Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept NCT04287348 | Vista Klinik | Phase 4 |
| Completed | A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Ma NCT04450329 | Samsung Bioepis Co., Ltd. | Phase 3 |
| Completed | Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD NCT04370379 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD NCT04058535 | Alteogen, Inc. | Phase 1 |
| Completed | A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD NCT04331730 | Alkahest, Inc. | Phase 2 |
| Completed | Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related NCT04047472 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration NCT05587062 | Cinnagen | Phase 3 |
| Completed | A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD NCT03953079 | Graybug Vision | Phase 2 |
| Completed | Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography NCT03909425 | Moorfields Eye Hospital NHS Foundation Trust | — |
| Completed | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age- NCT03834753 | Outlook Therapeutics, Inc. | Phase 3 |
| Completed | A Study Assessing AR-13503 Implant in Subjects With nAMD or DME NCT03835884 | Aerie Pharmaceuticals | Phase 1 |
| Enrolling By Invitation | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy NCT03999801 | AbbVie | Phase 2 |
| Terminated | Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration NCT03699618 | Johns Hopkins University | — |
| Completed | Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular NCT03930641 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration NCT03814291 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | CLN-0046: Treatment of AMD Subjects With OTX-TKI NCT03630315 | Ocular Therapeutix, Inc. | Phase 1 |
| Completed | Vessel Density in nAMD After Longterm Anti-VEGF Treatment Compared to Recently Started Anti-VEGF Treatment NCT03833830 | Dr. med. Katja Hatz | — |
| Completed | Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With W NCT03777254 | RemeGen Co., Ltd. | Phase 1 |
| Terminated | Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) NCT03630952 | Chengdu Kanghong Biotech Co., Ltd. | Phase 3 |
| Unknown | Post Intravitreal Injection Topical NSAID vs. Patching NCT03918590 | The New York Eye & Ear Infirmary | Phase 4 |
| Completed | ADVM-022 Intravitreal Gene Therapy for Wet AMD NCT03748784 | Adverum Biotechnologies, Inc. | Phase 1 |
| Completed | Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (A NCT03216538 | Feramda | Phase 1 / Phase 2 |
| Completed | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age- NCT03844074 | Outlook Therapeutics, Inc. | Phase 3 |
| Terminated | Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) NCT03577899 | Chengdu Kanghong Biotech Co., Ltd. | Phase 3 |
| Recruiting | Extension Study for the Port Delivery System With Ranibizumab (Portal) NCT03683251 | Hoffmann-La Roche | Phase 3 |
| Completed | A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Inje NCT03677934 | Hoffmann-La Roche | Phase 3 |
| Unknown | Intense Treatment Regimen With Intravitreal Aflibercept Injection NCT03594461 | Vitreous -Retina- Macula Consultants of New York | Phase 1 / Phase 2 |
| Completed | Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD NCT03479372 | PanOptica, Inc. | Phase 1 / Phase 2 |
| Unknown | Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Afliber NCT03468296 | Tennessee Retina | Phase 4 |
| Terminated | Pegcetacoplan (APL-2) in Neovascular AMD NCT03465709 | Apellis Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneratio NCT03387566 | Huabo Biopharm Co., Ltd. | Phase 1 |
| Completed | Timing of Low Vision Rehabilitation in Anti- Vascular Endothelial Growth Factor (VEGF) Therapy NCT03065907 | Johns Hopkins University | N/A |
| Completed | Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With NCT03386474 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD NCT03345082 | Opthea Limited | Phase 2 |
| Unknown | A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration NCT03021785 | Jiangsu T-Mab Biopharma Co.,Ltd | Phase 1 |
| Completed | ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) NCT03362190 | Ophthotech Corporation | Phase 2 |
| Completed | A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degene NCT03249740 | Graybug Vision | Phase 1 |
| Completed | Blood Coagulation Parameters in Patients Receiving Intravitreal Aflibercept for Age-related Macular Degenerati NCT03509623 | University Hospital of Patras | N/A |
| Completed | Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial NCT03066258 | REGENXBIO Inc. | Phase 1 / Phase 2 |
| Completed | Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related NCT03034772 | Wills Eye | Phase 2 / Phase 3 |
| Terminated | Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD NCT05571267 | IVERIC bio, Inc. | Phase 2 |
| Completed | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA6 NCT02867735 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration NCT02843490 | Johannes Gutenberg University Mainz | Phase 4 |
| Completed | Retinal Pigment Epithelial Characteristics in Eyes With Neovascular Age-related Macular Degeneration Following NCT03679156 | Hospital Hietzing | — |
| Completed | Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macu NCT02713204 | Regeneron Pharmaceuticals | Phase 2 |
| Withdrawn | Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD NCT02457026 | Duke University | N/A |
| Unknown | Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macula NCT02613559 | Jiangsu T-Mab Biopharma Co.,Ltd | Phase 1 |
| Completed | Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration NCT02507388 | Alcon Research | Phase 2 |
| Completed | Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 NCT02434328 | Alcon Research | Phase 3 |
| Completed | Study of DS-7080a for the Treatment of Macular Degeneration NCT02530918 | Daiichi Sankyo | Phase 1 |
| Terminated | SD-OCT Angiography NCT02510885 | Duke University | N/A |
| Completed | Photodynamic Therapy for PDA in NV AMD NCT02452840 | Duke University | — |
| Terminated | Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AM NCT02418754 | Regeneron Pharmaceuticals | Phase 2 |
| Completed | Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients Wit NCT02461771 | Apellis Pharmaceuticals, Inc. | Phase 1 |
| Completed | Efficacy and Safety of RTH258 Versus Aflibercept - Study 1 NCT02307682 | Alcon Research | Phase 3 |
| Completed | Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD NCT02367365 | Duke University | — |
| Completed | Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related NCT01997164 | Regeneron Pharmaceuticals | Phase 1 |
| Completed | NVAMD Satellite Study NCT02251366 | Johns Hopkins University | N/A |
| Completed | Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Deg NCT03744767 | Dr Irmela MANTEL | Phase 2 |
| Completed | Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD NCT02161575 | Novartis Pharmaceuticals | Phase 4 |
| Completed | An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfovea NCT02591914 | Retinal Consultants of Arizona | Phase 1 |
| Completed | Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD. NCT02321839 | Nagoya City University | Phase 4 |
| Unknown | Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD NCT02810808 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 |
| Completed | Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal In NCT01942213 | Prism Vision Group | — |
| Completed | Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thi NCT01958918 | Novartis Pharmaceuticals | Phase 4 |
| Unknown | Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. NCT01918878 | Hadassah Medical Organization | Phase 4 |
| Completed | Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degenera NCT01926977 | Arshad Khanani | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Function NCT01780935 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab NCT02309281 | Vista Klinik | Phase 4 |
| Completed | Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (A NCT01863199 | Retinal Consultants of Arizona | Phase 4 |
| Completed | Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients NCT01775124 | Novartis Pharmaceuticals | Phase 4 |
| Terminated | Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD). NCT01624636 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Deg NCT01678963 | Ohr Pharmaceutical Inc. | Phase 2 |
| Completed | Neovascular Age-related Macular Degeneration NCT01712035 | Oregon Health and Science University | — |
| Completed | A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With NCT01436864 | Chengdu Kanghong Biotech Co., Ltd. | Phase 3 |
| Completed | Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion NCT01291121 | Yonsei University | N/A |
| Completed | Safety and Tolerability Study for Age-Related Macular Degeneration NCT01485588 | Iconic Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular NCT01157715 | Chengdu Kanghong Biotech Co., Ltd. | Phase 2 |
| Completed | Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("We NCT00964795 | Regeneron Pharmaceuticals | Phase 3 |
| Completed | A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD NCT01242254 | Chengdu Kanghong Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration NCT01027468 | Medical University of Vienna | N/A |
| Unknown | Supplemental Adjuvants for Intracellular Nutrition and Treatment NCT00893724 | Mid-Atlantic Retina Consultations, Inc. | N/A |
| Completed | ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degenerati NCT00709527 | Ophthotech Corporation | Phase 1 |
| Completed | Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular A NCT00764738 | Retina Macula Institute | Phase 2 / Phase 3 |
| Unknown | Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration NCT00767949 | Lpath, Inc. | Phase 1 |
| Completed | Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice. NCT00858208 | Pfizer | — |
| Completed | The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study NCT00599222 | Anders Kvanta | Phase 3 |
| Withdrawn | Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Relate NCT00820742 | Pfizer | — |
| Completed | Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascu NCT00574093 | Fondazione G.B. Bietti, IRCCS | Phase 2 |
| Completed | A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In NCT00549055 | Pfizer | — |
| Unknown | The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degene NCT00640640 | Sheba Medical Center | N/A |
| Withdrawn | Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degene NCT00696592 | University of Padova | Phase 2 |
| Completed | Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD NCT00383370 | Regeneron Pharmaceuticals | Phase 1 |
| Unknown | Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone fo NCT00370539 | Shahid Beheshti University of Medical Sciences | Phase 3 |
| Completed | Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration NCT00967213 | Novartis Korea Ltd. | Phase 3 |
| Unknown | Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD NCT00370370 | Shahid Beheshti University of Medical Sciences | Phase 3 |
| Completed | An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD NCT00373659 | University of Miami | Phase 2 |
| Completed | Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study) NCT00344227 | University of Miami | Phase 2 |
| Completed | Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone NCT00685100 | Medical University of Vienna | Phase 3 |
| Withdrawn | Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macu NCT02450981 | Biocad | Phase 1 |